Login to Your Account

Abbvie wades into oncolytic viruses with Turnstone deal

By Cormac Sheridan
Staff Writer

Tuesday, October 10, 2017

DUBLIN – Turnstone Biologics Inc. entered a research, option and license agreement with Abbvie Inc., which it claims is the biggest such deal on record in the rapidly emerging area of oncolytic viruses.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription